(LABU) Direxion Daily S&P Biotech - Overview
Etf: Biotech, Leveraged, ETF, Swaps, Index
Dividends
| Dividend Yield | 1.16% |
| Yield on Cost 5y | 0.04% |
| Yield CAGR 5y | 146.15% |
| Payout Consistency | 54.1% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 93.1% |
| Relative Tail Risk | 3.65% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.03 |
| Alpha | 31.27 |
| Character TTM | |
|---|---|
| Beta | 2.625 |
| Beta Downside | 2.234 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.30% |
| CAGR/Max DD | 0.06 |
Description: LABU Direxion Daily S&P Biotech December 26, 2025
The Direxion Daily S&P Biotech Bull 3X Shares (LABU) seeks to deliver three times the daily performance of the S&P Biotechnology Select Industry Index by allocating at least 80 % of its net assets to derivatives-primarily swap agreements, index-linked securities, and ETFs-that together provide the leveraged exposure. Because the fund is classified as non-diversified, its holdings are concentrated in the biotech sub-industry defined by the Global Industry Classification Standards (GICS), and its performance is reset each trading day, which can cause compounding effects in volatile markets.
Key considerations for investors include the sector’s sensitivity to FDA approval pipelines (the biotech industry logged 38 novel drug approvals in Q3 2024, a 12 % YoY increase), R&D intensity (average R&D spend as a percentage of revenue remains above 25 % for the top 10 constituents), and the broader risk-on/risk-off environment that drives equity leverage demand. Additionally, leveraged ETFs like LABU typically exhibit higher expense ratios (≈0.95 % annual) and amplified tracking error compared to unleveraged peers, especially during periods of heightened volatility.
For a deeper quantitative breakdown, you might explore ValueRay’s sector heatmap to see how LABU’s exposure aligns with current biotech momentum.
What is the price of LABU shares?
Over the past week, the price has changed by +0.37%, over one month by +4.49%, over three months by +40.84% and over the past year by +72.93%.
Is LABU a buy, sell or hold?
What are the forecasts/targets for the LABU price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 200.9 | 20.7% |
LABU Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 643.6m USD (643.6m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 643.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 643.6m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 15.59% (E(643.6m)/V(643.6m) * Re(15.59%) + (debt-free company))
Discount Rate = 15.59% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)